Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 | P35462 | 4/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.57 |
| ▸ | HTR1A | P08908 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | DRD4 | P21917 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | GHSR | Q92847 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16299407 | 0.88 | DRD3 (0.85) | DRD3SIGMAR1HTR1ADRD2 | |
| SCHEMBL13741320 | 0.86 | HTR1A (0.75) | DRD3SIGMAR1HTR1ADRD2DRD4 | |
| SCHEMBL12128220 | 0.85 | DRD3 (0.58) | DRD3SIGMAR1HTR1ADRD2CHRM1 | |
| SCHEMBL8688812 | 0.83 | DRD3 (1.00) | DRD3SIGMAR1HTR1ADRD2 | |
| SCHEMBL10533962 | 0.82 | DRD3 (0.50) | DRD3SIGMAR1HTR1ADRD2DRD4 | |
| Hydrochloric Acid SCHEMBL10618356 | 0.81 | DRD3 (0.49) | DRD3SIGMAR1HTR1ADRD2DRD4 | |
| SCHEMBL12125958 | 0.80 | DRD3 (0.57) | DRD3SIGMAR1HTR1ADRD2DRD4 | |
| SCHEMBL13602471 | 0.75 | DRD3 (0.52) | DRD3SIGMAR1HTR1ADRD2DRD4 | |
| SCHEMBL5794759 | 0.75 | DRD3 (0.71) | DRD3SIGMAR1HTR1ADRD2CHRM1 | |
| SCHEMBL23248780 | 0.74 | HTR1A (0.46) | DRD3HTR1ADRD2DRD4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016151484-A1 | DISUBSTITUTED PIPERIDINE DERIVATIVES AS BUTYRYLCHOLINESTERASE INHIBITORS FOR USE IN THE TREATMENT OF ALZHEIMER | UNIVERZA V LJUBLJANI (SI) | 2016-09-29 | — | — | WO | disclosed |
| EP-2681221-B1 | TRICYCLIC INHIBITORS OF KINASES | ABBVIE INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-8710065-B2 | Tricyclic inhibitors of kinases | ABBVIE INC. (US) | 2014-04-29 | — | — | US | disclosed |
| CN-103703005-A | Tricyclic inhibitors of kinases | ABBOTT LAB | 2014-04-02 | — | — | CN | disclosed |
| EP-2681221-A1 | TRICYCLIC INHIBITORS OF KINASES | AbbVie Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012161812-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-08-30 | — | — | US | disclosed |
| US-7576238-B2 | Process for the preparation of substituted tetralin and substituted indane derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-08-18 | — | — | US | disclosed |
| US-20080096962-A1 | Process for the Preparation of Substituted Tetralin and Substituted Indane Derivatives | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | WEE1, WEE2, CDK1 | DRD3 3993/4885SIGMAR1 1147/4885HTR1A 2664/4885 |
| US-20080096962-A1 | Process for the Preparation of Substituted Tetralin and Substituted Indane Derivatives | TDO2, ITPA, TTI2 | DRD3 3097/4885SIGMAR1 3961/4885HTR1A 3243/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.